{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:17:04Z","timestamp":1790957824970,"version":"4.1.0"},"reference-count":146,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmune inflammation is caused by the loss of tolerance to specific self-antigens and can result in organ-specific or systemic disorders. Systemic autoimmune diseases affect a significant portion of the population with an increasing rate of incidence, which means that is essential to have effective therapies to control these chronic disorders. Unfortunately, several patients with systemic autoimmune diseases do not respond at all or just partially respond to available conventional synthetic disease-modifying antirheumatic drugs and targeted therapies. However, during the past few years, some new medications have been approved and can be used in real-life clinical settings. Meanwhile, several new candidates appeared and can offer promising novel treatment options in the future. Here, we summarize the newly available medications and the most encouraging drug candidates in the treatment of systemic lupus erythematosus, rheumatoid arthritis, Sj\u00f6gren\u2019s disease, systemic sclerosis, systemic vasculitis, and autoimmune myositis.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1249500","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T04:56:50Z","timestamp":1710478610000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Novel and potential future therapeutic options in systemic autoimmune diseases"],"prefix":"10.3389","volume":"15","author":[{"given":"Lili","family":"Balogh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Ol\u00e1h","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"S\u00e1nta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00f3ra","family":"Majerhoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"N\u00e9meth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78088","article-title":"Mechanisms of human autoimmunity","volume":"125","author":"Rosenblum","year":"2015","journal-title":"J Clin Invest"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3731","article-title":"The multiple pathways to autoimmunity","volume":"18","author":"Theofilopoulos","year":"2017","journal-title":"Nat Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02520322","article-title":"Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study","volume":"17","author":"Furie","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sjogren\u2019s syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev257","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sjogren\u2019s syndrome: the BELISS open-label phase II study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14397595.2019.1583832","article-title":"Safety and tolerability of sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study","volume":"30","author":"Takeuchi","year":"2020","journal-title":"Mod Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","article-title":"The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study","volume":"32","author":"Chen","year":"2023","journal-title":"Lupus"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.1727","article-title":"Efficacy and safety of telitacicept, a novel BLyS\/APRIL dual inhibitor, in patients with sysytemic lupus erythematosus: a phase 3, randomized, placebo-controlled 52-week study","volume":"82","author":"Wang","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.3110","article-title":"Safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; ANTI-BAFFR mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE)","volume":"82","author":"Cort\u00e9s-Hern\u00e1ndez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201183","article-title":"Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of phase II rheumatoid arthritis programs","volume":"48","author":"Kavanaugh","year":"2021","journal-title":"J Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/art.40420","article-title":"Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor alpha monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis","volume":"70","author":"Burmester","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221865","article-title":"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"81","author":"Cid","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003317","article-title":"A phase 2, randomized, double-blind, placebo-controlled, mechanistic insight and dosage optimization study of the efficacy and safety of dazodalibep (VIB4920\/HZN4920) in patients with rheumatoid arthritis having inadequate response to conventional\/biological DMARDs","volume":"74","author":"Kivitz","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003317","article-title":"The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis","volume":"9","author":"Kivitz","year":"2023","journal-title":"RMD Open"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.7074","article-title":"Dazodalibep (VIB4920\/HZN4920) in Sj\u00f6gren\u2019s subjects with an unacceptable symptom burden: safety and efficacy from a phase 2, randomized, double-blind study","volume":"82","author":"Clair","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-219876","article-title":"Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study","volume":"81","author":"Nasonov","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222630","article-title":"Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study","volume":"81","author":"Feist","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201302","article-title":"Olokizumab versus placebo or adalimumab in rheumatoid arthritis","volume":"387","author":"Smolen","year":"2022","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.2519","article-title":"POS0881- Efficacy and safety of subcutaneous brodalumab, a fully human anti-IL-17RA monoclonal antibody, for systemic sclerosis with moderate-to-severe skin thickening: a multicenter, randomized, placebo-controlled, double-blind phase 3 study","volume":"81","author":"Fukasawa","year":"2022","journal-title":"Ann Rheumatic Dis"},{"key":"B39","article-title":"Tofacitinib in early diffuse cutaneous systemic sclerosis\u2014 Results of phase I\/II investigator-initiated, double-blind randomized placebo-controlled trial","volume":"71","author":"Khanna","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1186\/s13063-021-05520-1","article-title":"Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial","volume":"22","author":"Venhoff","year":"2021","journal-title":"Trials"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40265-021-01643-6","article-title":"Avacopan: first approval","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: A european multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222776","article-title":"Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study","volume":"81","author":"Bettiol","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00311-2019","article-title":"Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"6","author":"Kent","year":"2020","journal-title":"ERJ Open Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.3917","article-title":"Apremilast in recalcitrant cutaneous dermatomyositis: A nonrandomized controlled trial","volume":"158","author":"Bitar","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-eular.527","article-title":"LB0002 safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: A randomised, double-blind, placebo-controlled, phase IIa proof-of-concept trial","volume":"72","author":"MaChado","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2092470","article-title":"Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis","volume":"15","author":"van Gelder","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221122148","article-title":"Multitarget therapy versus monotherapy as induction treatment for lupus nephritis: A meta-analysis of randomized controlled trials","volume":"31","author":"Lee","year":"2022","journal-title":"Lupus"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00316","article-title":"B cell therapy in systemic lupus erythematosus: from rationale to clinical practice","volume":"7","author":"Parodis","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B55","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1159794","article-title":"Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review","volume":"10","author":"Sans-Pola","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22921","article-title":"Use of rituximab in systemic lupus erythematosus: A single center experience over 14 years","volume":"69","author":"Aguiar","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2023"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of belimumab after rituximab in systemic lupus erythematosus: A randomized controlled trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann Intern Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key042","article-title":"Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab","volume":"57","author":"Masoud","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew267","article-title":"Successful treatment of life-threatening autoimmune haemolytic anaemia with ofatumumab in a patient with systemic lupus erythematosus","volume":"55","author":"Karageorgas","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"B64","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12969-018-0278-1","article-title":"Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C delta","volume":"16","author":"Lei","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320981137","article-title":"Ofatumumab use in juvenile systemic lupus erythematosus: A single centre experience","volume":"30","author":"Cinar","year":"2021","journal-title":"Lupus"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab827","article-title":"Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab","volume":"61","author":"Reddy","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket284","article-title":"Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus","volume":"53","author":"Quartuccio","year":"2014","journal-title":"Rheumatol (Oxford)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316686703","article-title":"The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis","volume":"26","author":"Zhang","year":"2017","journal-title":"Lupus"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319896018","article-title":"Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience","volume":"29","author":"Segarra","year":"2020","journal-title":"Lupus"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1432331","article-title":"Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus","volume":"28","author":"Ishii","year":"2018","journal-title":"Mod Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.12.1823","article-title":"BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha\/beta induction","volume":"194","author":"Dzionek","year":"2001","journal-title":"J Exp Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222212","article-title":"Biological impact of iberdomide in patients with active systemic lupus erythematosus","volume":"81","author":"Lipsky","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/BOR.0000000000000924","article-title":"Low-dose interleukin-2 therapy: a promising targeted therapeutic approach for systemic lupus erythematosus","volume":"35","author":"Akbarzadeh","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.2244","article-title":"Efavaleukin alpha, a novel IL-2 mutein, selectively expands regulatory T cells in patients with SLE: final results of a phase 1b multiple ascending dose study","volume":"81","author":"Tchao","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B87","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/antib12010020","article-title":"Intravenous immunoglobulins as immunomodulators in autoimmune diseases and reproductive medicine","volume":"12","author":"Velikova","year":"2023","journal-title":"Antibodies (Basel)"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: A phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.601344","article-title":"Largely accelerated arterial aging in rheumatoid arthritis is associated with inflammatory activity and smoking in the early stage of the disease","volume":"11","author":"Mong","year":"2020","journal-title":"Front Pharmacol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01129-y","article-title":"Filgotinib: A clinical pharmacology review","volume":"61","author":"Namour","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial","volume":"80","author":"Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S219586","article-title":"JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data","volume":"13","author":"Harrington","year":"2020","journal-title":"J Inflamm Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1794103","article-title":"Efficacy and safety of peficitinib in rheumatoid arthritis","volume":"30","author":"Kaneko","year":"2020","journal-title":"Mod Rheumatol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/1759720X17752036","article-title":"Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-alpha in rheumatoid arthritis: focus on mavrilimumab","volume":"10","author":"Cook","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B96","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/14397595.2014.896448","article-title":"Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: Findings from a Phase IIa study","volume":"25","author":"Takeuchi","year":"2015","journal-title":"Modern Rheumatol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202450","article-title":"Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar6584","article-title":"A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity","volume":"11","author":"Karnell","year":"2019","journal-title":"Sci Transl Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.28612","article-title":"Discovery and characterization of olokizumab A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling","volume":"6","author":"Shaw","year":"2014","journal-title":"Mabs"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-022-01315-0","article-title":"Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials","author":"Ho Lee","year":"2023","journal-title":"Z Rheumatol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","article-title":"Sjogren syndrome","volume":"2","author":"Brito-Zeron","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sjogren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.1728","article-title":"Efficacy and safety of telitacicept, a novel BLyS\/APRIL dual inhibitor, in patients with primary Sj\u00f6gren\u2019s syndrome: a phase 2, randomized, placebo-controlled 24-week study","volume":"82","author":"Xu","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead265","article-title":"Efficacy and safety of telitacicept in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial","author":"Xu","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-KCR.56","article-title":"Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study","volume":"74","author":"Kahlenberg","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"Acharya","year":"2020","journal-title":"Rheumatol Int"},{"key":"B113","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1038\/cti.2013.2","article-title":"Interleukin-6: a new therapeutic target in systemic sclerosis","volume":"2","author":"O\u2019Reilly","year":"2013","journal-title":"Clin Transl Immunol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1038\/s41467-021-26099-w","article-title":"Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis","volume":"12","author":"Kuzumi","year":"2021","journal-title":"Nat Commun"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30237-X","article-title":"Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial","volume":"2","author":"Chung","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B117","article-title":"Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis","volume":"151","author":"Mavalia","year":"1997","journal-title":"Am J Pathol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.2115","article-title":"OP0172 Brentuximab Vedontin for skin involvment in refractory Diffuse Cutaneous Systemic Sclerosis,interim results of a phase IIB open-label trial","volume":"80","author":"Fernandez-Codina","year":"2021","journal-title":"Ann Rheumatic Dis"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1813569","article-title":"Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis","volume":"16","author":"Liakouli","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13075-019-1981-0","article-title":"Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)","volume":"21","author":"Pan","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: A multicenter, double-blind, randomized, placebo-controlled trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez526","article-title":"In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors","volume":"59","author":"Kitanaga","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B123","doi-asserted-by":"publisher","first-page":"103168","DOI":"10.1016\/j.autrev.2022.103168","article-title":"JAK inhibitors and systemic sclerosis: A systematic review of the literature","volume":"21","author":"Moriana","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.859330","article-title":"JAK1\/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis","volume":"9","author":"Hou","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000907","article-title":"Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit","volume":"34","author":"Kakkar","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13075-016-1021-2","article-title":"Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study","volume":"18","author":"Schiopu","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B128","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41572-021-00327-5","article-title":"Large-vessel vasculitis","volume":"7","author":"Pugh","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.621098","article-title":"Innate and adaptive immunity in giant cell arteritis","volume":"11","author":"Akiyama","year":"2020","journal-title":"Front Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa281","article-title":"Tofacitinib in patients with refractory Takayasu\u2019s arteritis","volume":"59","author":"Li","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221961","article-title":"Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study","volume":"81","author":"Koster","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220832","article-title":"Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study","volume":"81","author":"Kong","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B133","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.313","article-title":"Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"83","author":"Gou","year":"2013","journal-title":"Kidney Int"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164646","article-title":"Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study","volume":"11","author":"Bekker","year":"2016","journal-title":"PloS One"},{"key":"B136","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.06.004","article-title":"Update on eosinophilic granulomatosis with polyangiitis","volume":"68","author":"Furuta","year":"2019","journal-title":"Allergol Int"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1361.053","article-title":"Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome","volume":"1051","author":"Hellmich","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2012.642359","article-title":"Benralizumab\u2013a humanized mAb to IL-5Ralpha with enhanced antibody-dependent cell-mediated cytotoxicity\u2013a novel approach for the treatment of asthma","volume":"12","author":"Ghazi","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.221219","article-title":"Response to treatment with tofacitinib in 11 patients with refractory granulomatosis with polyangiitis","volume":"50","author":"Linde","year":"2023","journal-title":"J Rheumatol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002742","article-title":"Daratumumab for the treatment of refractory ANCA-associated vasculitis","volume":"9","author":"Ostendorf","year":"2023","journal-title":"RMD Open"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.0152","article-title":"Daratumumab for a patient with refractory antineutrophil cytoplasmatic antibody-associated vasculitis","volume":"183","author":"Rixecker","year":"2023","journal-title":"JAMA Intern Med"},{"key":"B143","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B144","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1212\/WNL.98.18_supplement.969","article-title":"A randomized, double-blind, placebo-controlled study of arimoclomol in patients with inclusion body myositis (S23.010)","volume":"98","author":"MaChado","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"Muller","year":"2023","journal-title":"Lancet"},{"key":"B146","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1249500\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T04:56:54Z","timestamp":1710478614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1249500\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":146,"alternative-id":["10.3389\/fimmu.2024.1249500"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1249500","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"article-number":"1249500"}}